SCHEMBL2654895

SCHEMBL2654895

O=C(O)C(=O)c1ccc(SC2CC2)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.37
CA12 O43570 3/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA4 P22748 3/20 0.36
CA6 P23280 3/20 0.36
CA7 P43166 3/20 0.36
CA9 Q16790 3/20 0.36
CA13 Q8N1Q1 3/20 0.36
CA14 Q9ULX7 3/20 0.36
CA5B Q9Y2D0 3/20 0.36
KMO O15229 2/20 0.36
HPGD P15428 1/20 0.35
CPT1B Q92523 1/20 0.35
GRIK1 P39086 4/20 0.34
GRIA2 P42262 4/20 0.34
TAS1R3 Q7RTX0 2/20 0.34
TAS1R2 Q8TE23 2/20 0.34
CA3 P07451 2/20 0.34
SRD5A2 P31213 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1857913 0.94 CA2 (0.43) TSHRCA12CA1CA2CA4
SCHEMBL3509742 0.83 CPT1B (0.36) CA12CA1CA2CA4CA6
SCHEMBL4629130 0.81 CES2 (0.40) TSHRCA2HPGDCPT1BTAS1R3
SCHEMBL2655589 0.79 TSHR (0.41) TSHRHPGDTAS1R3TAS1R1
SCHEMBL16506296 0.79 KMO (0.65) TSHRCA12CA1CA2CA4
SCHEMBL30717807 0.79 KMO (0.65) TSHRCA12CA1CA2CA4
SCHEMBL2162295 0.77 TSHR (0.41) TSHRCPT1BTAS1R3SRD5A2TAS1R1
SCHEMBL19618038 0.75 KMO (0.49) CA12CA1CA2CA4CA6
SCHEMBL17996737 0.75 SLC6A4 (0.40) CA12CA1CA2CA4CA6
SCHEMBL17996736 0.75 SLC6A4 (0.35) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293730-A1 Tricyclo Substituted Amides PROSIDION LIMITED (GB) 2008-11-27 US disclosed
US-20080293730-A1 Tricyclo Substituted Amides PROSIDION LIMITED (GB) 2008-11-27 US disclosed
US-20080293730-A1 Tricyclo Substituted Amides PROSIDION LIMITED (GB) 2008-11-27 US disclosed
EP-1948645-A1 TRICYCLO SUBSTITUTED AMIDES Prosidion Limited (GB) 2008-07-30 EP disclosed
WO-2007051846-A1 TRICYCLO SUBSTITUTED AMIDES PROSIDION LTD (GB) 2007-05-10 WO disclosed
WO-2007051846-A1 TRICYCLO SUBSTITUTED AMIDES PROSIDION LTD (GB) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293730-A1 Tricyclo Substituted Amides GPR119, SLC5A2, SLC5A1 TSHR 827/4885CA12 1287/4885CA1 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.